论文部分内容阅读
目的观察尿激酶联合阿托伐他汀治疗ST段抬高型心肌梗死患者的临床效果。方法选取近两年接受治疗的ST段抬高型心肌梗死患者100例,将其随机分为对照组和实验组,每组50例,对照组仅行常规治疗,实验组在常规治疗的基础上服用阿托伐他汀,观察比较两组患者治疗后临床指标的改善情况和不良反应发生率。结果对照组治疗后肌钙蛋白Ⅰ(c Tn I)和肌酸激酶同工酶(CK-MB)峰值浓度分别为(2.9±1.3)ng/ml、(155.5±68.2)ng/ml,明显高于实验组的(2.3±1.0)ng/ml、(145.3±62.8)ng/ml;对照组治疗后c Tn I和CK-MB分别恢复时间(80.1±19.0)h、(31.3±7.4)h,明显高于实验组的(74.6±18.2)h、(25.5±6.7)h,两组比较差异有统计学意义(P<0.05);实验组总不良反应的发生率(12.00%)低于对照组(42.00%),差异有统计学意义(P<0.05)。结论尿激酶联合阿托伐他汀治疗ST段抬高型心肌梗死患者治疗效果优越,心脏再次缺血危险降低,值得临床应用并推广。
Objective To observe the clinical effect of urokinase combined with atorvastatin on patients with ST segment elevation myocardial infarction. Methods One hundred patients with ST-segment elevation myocardial infarction who were treated in the past two years were selected and randomly divided into control group and experimental group, with 50 cases in each group. The control group was treated only routinely. On the basis of routine treatment Atorvastatin was taken and observed to compare the improvement of clinical indexes and the incidence of adverse reactions after treatment in both groups. Results The peak concentrations of cTn I and CK-MB in the control group after treatment were (2.9 ± 1.3) ng / ml and (155.5 ± 68.2) ng / ml, respectively, which were significantly higher (2.3 ± 1.0) ng / ml and (145.3 ± 62.8) ng / ml respectively in the experimental group. The recovery time of cTn I and CK-MB in the control group were (80.1 ± 19.0) h and (31.3 ± 7.4) (74.6 ± 18.2) h, (25.5 ± 6.7) h in the experimental group, the difference between the two groups was statistically significant (P <0.05). The incidence of adverse reactions in the experimental group (12.00%) was lower than that in the control group (42.00%), the difference was statistically significant (P <0.05). Conclusion Urokinase combined with atorvastatin in patients with ST-elevation myocardial infarction is superior in treatment, and the risk of re-ischemic heart is reduced, which is worthy of clinical application and promotion.